The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 2 briefings matching “metformin”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ENDOCRINOLOGY · REAL-WORLD COHORT

Metformin-supportive nutrition: When gut microbes eat drugs

Zhao et al. identify microbial AdhE as a metformin-degrading enzyme in metformin low-responders and propose enzyme-based microbiome intervention as a strategy to rescue therapy. Published in Cell metabolism, these peer-reviewed endocrinology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

ENDOCRINOLOGY · RANDOMIZED CLINICAL TRIAL

Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial

Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readDiabetes CareNov 5, 2026

Interactive Fact Check